72 related articles for article (PubMed ID: 18318756)
21. Stiffness of the abdominal aorta in beta-thalassemia major patients related with body iron load.
Ulger Z; Aydinok Y; Gurses D; Levent E; Ozyurek AR
J Pediatr Hematol Oncol; 2006 Oct; 28(10):647-52. PubMed ID: 17023824
[TBL] [Abstract][Full Text] [Related]
22. Arterial elasticity identified by pulse wave analysis and its relation to endothelial function in patients with coronary artery disease.
Tao J; Liu DH; Wang LC; Wang JM; Wang Y; Yang Z; Lou ZF; Tang AL
J Hum Hypertens; 2007 Feb; 21(2):149-53. PubMed ID: 17082797
[TBL] [Abstract][Full Text] [Related]
23. Effect of iron chelators on labile iron and oxidative status of thalassaemic erythroid cells.
Prus E; Fibach E
Acta Haematol; 2010; 123(1):14-20. PubMed ID: 19923794
[TBL] [Abstract][Full Text] [Related]
24. Increased levels of C-reactive protein in hypothyroid patients and its correlation with arterial stiffness in the common carotid artery.
Nagasaki T; Inaba M; Shirakawa K; Hiura Y; Tahara H; Kumeda Y; Ishikawa T; Ishimura E; Nishizawa Y
Biomed Pharmacother; 2007; 61(2-3):167-72. PubMed ID: 17383146
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of carotid artery dynamics & correlation with cardiac & hepatic iron in β-thalassaemia patients.
Merchant RH; Chate S; Ahmed J; Ahmad N; Karnik A; Jankaria B
Indian J Med Res; 2016 Apr; 143(4):443-8. PubMed ID: 27377500
[TBL] [Abstract][Full Text] [Related]
26. Paradoxically increased ferritin level in a beta-thalassemia major patient following the start of deferasirox chelation therapy.
Ricchi P; Ammirabile M; Spasiano A; Costantini S; Cinque P; Di Matola T; Prossomariti L
Acta Haematol; 2010; 123(2):117-20. PubMed ID: 20068283
[TBL] [Abstract][Full Text] [Related]
27. Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome.
List AF; Baer MR; Steensma DP; Raza A; Esposito J; Martinez-Lopez N; Paley C; Feigert J; Besa E
J Clin Oncol; 2012 Jun; 30(17):2134-9. PubMed ID: 22547607
[TBL] [Abstract][Full Text] [Related]
28. The effects of low-dose fluvastatin and valsartan combination on arterial function: a randomized clinical trial.
Lunder M; Janić M; Jug B; Sabovič M
Eur J Intern Med; 2012 Apr; 23(3):261-6. PubMed ID: 22385885
[TBL] [Abstract][Full Text] [Related]
29. Exjade (ICL 670): A new oral iron chelator.
Agarwal MB
J Assoc Physicians India; 2006 Mar; 54():214-7. PubMed ID: 16800349
[TBL] [Abstract][Full Text] [Related]
30. Circulating CD133(+)VEGFR2 (+) and CD34 (+)VEGFR2 (+) cells and arterial function in patients with beta-thalassaemia major.
Cheung YF; Chan S; Yang M; Ye JY; Ha SY; Wong SJ; Chan GC
Ann Hematol; 2012 Mar; 91(3):345-52. PubMed ID: 21808992
[TBL] [Abstract][Full Text] [Related]
31. Treatment with deferasirox (Exjade) effectively decreases iron burden in patients with thalassaemia intermedia: results of a pilot study.
Voskaridou E; Plata E; Douskou M; Papadakis M; Delaki EE; Christoulas D; Terpos E
Br J Haematol; 2010 Jan; 148(2):332-4. PubMed ID: 19863539
[No Abstract] [Full Text] [Related]
32. Effects of deferasirox and deferiprone on cellular iron load in the human hepatoma cell line HepaRG.
Gaboriau F; Leray AM; Ropert M; Gouffier L; Cannie I; Troadec MB; Loréal O; Brissot P; Lescoat G
Biometals; 2010 Apr; 23(2):231-45. PubMed ID: 19997770
[TBL] [Abstract][Full Text] [Related]
33. Increased plasma neopterin levels are associated with reduced endothelial function and arterial elasticity in hypertension.
Zhang YY; Tong XZ; Xia WH; Xie WL; Yu BB; Zhang B; Chen L; Tao J
J Hum Hypertens; 2016 Jul; 30(7):436-41. PubMed ID: 26202692
[TBL] [Abstract][Full Text] [Related]
34. Reversal of iron-induced dilated cardiomyopathy during therapy with deferasirox in beta-thalassemia.
Trad O; Hamdan MA; Jamil A; Khanani MF; Ishaqi MK; Shamsi A; Hayek M
Pediatr Blood Cancer; 2009 Mar; 52(3):426-8. PubMed ID: 18985743
[TBL] [Abstract][Full Text] [Related]
35. Flow-mediated dilation benefits of mesoglycan in peripheral artery disease.
Gossetti B; Antignani PL; Jabbour J; Martinelli O
Int Angiol; 2015 Aug; 34(4):398-406. PubMed ID: 25972138
[TBL] [Abstract][Full Text] [Related]
36. Predictors of non-adherence to follow-up visits and deferasirox chelation therapy among jordanian adolescents with Thalassemia major.
Al-Kloub MI; A Bed MA; Al Khawaldeh OA; Al Tawarah YM; Froelicher ES
Pediatr Hematol Oncol; 2014 Oct; 31(7):624-37. PubMed ID: 25116329
[TBL] [Abstract][Full Text] [Related]
37. Ventriculo-vascular interactions in patients with beta thalassaemia major.
Cheung YF; Ha SY; Chan GC
Heart; 2005 Jun; 91(6):769-73. PubMed ID: 15894772
[TBL] [Abstract][Full Text] [Related]
38. IMPAIRED ENDOTHELIAL FUNCTION IN PEDIATRIC HEMOGLOBIN E/β-THALASSEMIA PATIENTS WITH IRON OVERLOAD.
Aphinives C; Kukongviriyapan U; Jetsrisuparb A; Kukongviriyapan V; Somparn N
Southeast Asian J Trop Med Public Health; 2014 Nov; 45(6):1454-63. PubMed ID: 26466432
[TBL] [Abstract][Full Text] [Related]
39. Deferasirox increases BU blood concentrations.
Sweiss K; Patel P; Rondelli D
Bone Marrow Transplant; 2012 Feb; 47(2):315-6. PubMed ID: 21460865
[No Abstract] [Full Text] [Related]
40. Deferasirox improves liver fibrosis in beta-thalassaemia major patients. A five-year longitudinal study from a single thalassaemia centre.
Sousos N; Sinakos E; Klonizakis P; Adamidou D; Daniilidis A; Gigi E; Vetsiou E; Tsioni K; Mandala E; Vlachaki E
Br J Haematol; 2018 Apr; 181(1):140-142. PubMed ID: 28106901
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
